Keyword: Pear Therapeutics
Pear Therapeutics is expanding its app-based platform to conditions outside of the brain and mental health through a GI-focused deal with Ironwood.
Sandoz pulled the plug on its commercialization partnership with Pear Therapeutics, ending its experiment with digital treatments for substance abuse.
Pear Therapeutics' prescription apps for substance abuse are designed to not only complement medication-assisted treatments but also reproduce the effects of face-to-face psychology sessions.
Pear Therapeutics and Novartis’ new digital treatment is designed to be given alongside a disease-modifying therapy for relapsing multiple sclerosis.
Pear Therapeutics aims to develop digital therapeutics that reproduce the changes seen in a patient’s neural circuitry following traditional, face-to-face sessions of cognitive behavioral therapy.
These are the ideas that can move the needle. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today.
Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.
The agreement sees Novartis work with Pear to get a schizophrenia app to market while developing an earlier-stage treatment for multiple sclerosis.
The series B sets Pear up to market its recently approved substance-use disorder app while working to bring follow-up digital therapies to market.